Skip to main content

Our Journey
Our Technology
Pipeline

Leadership
Investors
Get in Touch

Press Releases

Overview
Press Releases
Events
Presentations
Corporate Governance
Analyst Coverage
Stock Information
SEC Filings
Investor FAQs
Email Alerts

Investor Contact

Jill Steier
Executive Director, Investor Relations & Corporate Communications
Jill.Steier@kalarx.com
781-810-4086

Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200

Press Releases

Keyword Search

Year

May 16, 2022

Kala Reports First Quarter 2022 Financial Results and Provides Corporate Update

May 09, 2022

Kala Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call

May 03, 2022

Kala Pharmaceuticals Announces New Commercial and Medicare Coverage for EYSUVIS®

May 01, 2022

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

Apr 04, 2022

Kala Pharmaceuticals to Present Phase 1b Clinical Data for KPI-012 in Patients with PCED at 2022 ARVO Annual Meeting

Mar 29, 2022

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Mar 23, 2022

Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call

Mar 08, 2022

Kala Pharmaceuticals Announces EYSUVIS® Now Covered on UnitedHealthcare Commercial and Cigna Medicare

Feb 18, 2022

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Our Journey
Our Technology
Pipeline
Leadership
- Management Team
- Board of Directors
Investors
Get in Touch

©2022 Kala Pharmaceuticals All rights reserved. AMPPLIFY is a trademark and INVELTYS is a registered trademark of Kala Pharmaceuticals.
US-INV-1900184 January 2022

Terms of Use Privacy Statement Accessibility Policy